CRISPR Editing of CCR5 and HIV-1 Facilitates Viral Elimination in Antiretroviral Drug-Suppressed Virus-Infected Humanized Mice

Treatment of HIV-1ADA-infected CD34+ NSG-humanized mice with long-acting ester prodrugs of cabotegravir, lamivudine, and abacavir in combination with native rilpivirine was followed by dual CRISPR-Cas9 C-C chemokine receptor type five (CCR5) and HIV-1 proviral DNA gene editing.